MNPR Stock Summary and Trading Ideas (Monopar Therapeutics | NASDAQ:MNPR)

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics trades on the NASDAQ stock market under the symbol MNPR.

As of April 30, 2024, MNPR stock price climbed to $0.66 with 54,580 million shares trading.

MNPR has a beta of 1.93, meaning it tends to be more sensitive to market movements. MNPR has a correlation of 0.02 to the broad based SPY ETF.

MNPR has a market cap of $9.81 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, MNPR stock traded as high as $6.98 and as low as $.27.

The top ETF exchange traded funds that MNPR belongs to (by Net Assets): VXF.

MNPR has underperformed the market in the last year with a price return of -41.3% while the SPY ETF gained +22.3%. However, in the short term, MNPR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +83.4% vs +2.5% return in SPY. But in the last 2 weeks, MNPR shares have been beat by the market, returning -12.6% compared to an SPY return of -0.5%.

MNPR support price is $.60 and resistance is $.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNPR stock will trade within this expected range on the day.